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Case presentations
A 24-year-old man (Patient 1) was first found to be hypertensive
(blood pressure, 150/95 mm Hg) at the age of 8 years, when he
presented to a physician because of headaches.He was discharged
untreated. Approximately 7 years later he again was found to be
hypertensive (blood pressure, 180/120 mm Hg) and over succeeding
years was treated with varying success with several drugs, including
propranolol, atenolol, and indapamide. When he was first seen at age 24
in the Medical Research Council Blood Pressure Unit, his blood
pressure was poorly controlled on propranolol (80 mg/day). Treatment
was withdrawn and after 4 weeks his blood pressure was 210/106 mm
Hg. At that time his 29-year-old brother (Patient 2) also was referred to
the Unit with headaches and hypertension (blood pressure, 160/106 mm
Hg). Physical examination of both patients was within normal limits
except for hypertension. Both patients had normal routine blood
studies, and neither had any clinical or biochemical evidence of renal
disease or abnormal catecholamine secretion.
The patients' father was apparently severely hypertensive, but no
records were available. He had suffered two strokes at the ages of 38
and 45 years, the second of which was fatal. Their mother also has
hypertension and has suffered one transient cerebral ischemic attack.
Three paternal uncles were hypertensive; all 3 died at relatively early
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ages (42, 52, and 61 years). Whether any of these relatives had
hyperaldosteronism is unknown.
Results of special studies in both patients appear in Table 1. Plasma
aldosterone concentration was high (upper limit of normal, 18 ng/dl) and
plasma renin concentration low (normal, 10—50 tU/liter) in both cases.
Plasma cortisol concentration was normal, suggesting normal ACTH
secretion, but interestingly plasma 1 1-deoxycorticosterone (DOC), an-
other mineralocorticoid, was slightly raised (normal range, 4-16 ng/dl).
Electrolyte determination revealed hypokalemia; serum sodium con-
centration was normal. Total-body sodium and potassium were mea-
sured before and after the administration of 2mg of dexamethasone (0.5
mg four times daily) for 4 weeks. The fall in plasma cortisol concentra-
tion to undetectable levels (with dexamethasone) indicated suppression
of ACTH secretion to subnormal levels during treatment. This decrease
in cortisol levels occurred concurrently with a decrease in the concen-
trations of plasma aldosterone to low-normal and of plasma DOC to low
levels. These hormonal changes were associated with an increase of
plasma potassium concentration to normal and a slight fall in plasma
sodium concentration. Total-body potassium increased and in each
patient total-body sodium fell more than 300 mEq. The decrease was
accompanied by a return of blood pressure to the normal range. The
biochemical abnormalities and hypertension recurred in 4 weeks after
dexamethasone was withdrawn.
Infusion of ACTH while the patients were untreated gave dose-
response curves for aldosterone and DOC that were steeper than
normal, whereas that for cortisol was normal, The dose-response curve
for aldosterone was unaffected by dexamethasone treatment (Fig. 1).
In Patient 1, the side effects of dexamethasone were unacceptable,
and he is being treated successfully with amiloride, a potassium-sparing
diuretic. Patient 2 remains well-controlled on a low dose of dexameth-
asone (0.25 mg/day).
Discussion
DR. J. I. S. ROBERTSON (Clinical Scientist and Consultant
Physician, Medical Research Council Blood Pressure Unit,
Western Infirmary, Glasgow, Scotland, U.K.): In this Forum,
we shall be considering mainly the body content of sodium but
also of potassium in various hypertensive syndromes, espe-
cially essential hypertension. Before considering the details,
however, I have asked my associate, Dr. Robert Fraser, to
describe briefly a rare, but most interesting disease, hyperten-
sion resulting from dexamethasone-suppressible aldosterone
excess, which provides the springboard of this discussion.
Several of my colleagues will contribute to this Forum.
DR. R. FRASER (Non-clinical Scientist, MRC Blood Pressure
Unit, Western Infirmary): Primary hyperaldosteronism, a hy-
pertensive condition associated with potassium loss and sodium
retention, is the result of autonomous oversecretion of the
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Patient 1 Patient 2
Untreated Treateda Untreated Treateda
Blood pressure 210/112 134/84 160/106 132/86
mm Hg
Serum K 3.3 4.2 3.5 4.2
mEqlliter
Total body K 3995 4384 4355 4655
mEqlliter
Serum Na 142 139 141 139
mEqiliter
Total body Na 4029 3656 3817 3494
mEq/liter (—373) (—323)
Plasma active renin <3 68 <3 49
U/ml
Plasma aldosterone 27 4 20 2
ng/dl
Plasma cortisol 15 <1 13 <1
j.g/dl
Plasma DOC 19 1 21 1
ng/dl
mineralocorticoid aldosterone. The rare variant of this disease,
dexamethasone-suppressible hyperaldosteronism, originally
was described by Sutherland et al in 1966 [1]. Diagnosis is based
on the general criteria for primary hyperaldosteronism, that is,
high plasma aldosterone concentration or aldosterone secretion
rate, low plasma renin concentration and hypokalemia, as well
as the special criterion for this disease, sustained correction of
blood pressure and biochemical abnormalities by administra-
tion of the synthetic glucocorticoid dexamethasone. Dexame-
thasone suppresses ACTH secretion; aldosterone secretion,
which is supersensitive to ACTH infusion in this condition, is
also suppressed. As the condition probably is inherited as an
autosomal dominant factor, other members of the family are
likely to be affected. The patients presented today thus fulfill
each of these criteria for diagnosis, and they also illustrate the
sodium-dependent nature of the raised blood pressure. We have
reported on these patients in detail elsewhere [2].
Assessment of whok-body sodium and potassium could
throw important light on the pathogenesis and treatment of
human hypertension. Perhaps surprisingly, this approach has
interested only a few centers and remains less than fully
explored. There are obvious limitations; total-body measure-
ments do not reveal what could be critical aspects of the
distribution of electrolytes within the organism. Nevertheless,
it is my opinion and that of my colleagues that, despite the
reservations, this approach can provide important pathophysi-
ologic insights into human hypertension.
DR. ROBERTSON: In his presentation of these 2 patients, Dr.
Fraser showed data on an unusual, but extremely interesting,
familial syndrome in which an excess of aldosterone, which is
abnormally dependent on ACTH secretion, leads to hyperten-
sion, expansion of exchangeable sodium, and suppression of
the renin-angiotensin system. When ACTH secretion is lowered
by the administration of dexamethasone, body sodium content
falls and, in parallel, arterial pressure decreases. The remark-
able correlation between body sodium and blood pressure in
this rare syndrome provides us an opportunity to consider body
Aldosterone 60
ng/100 ml
Corticosterone 2000
ng/lOOml 1000
500
11-deoxy- 120
corticosterone 90
ng/lOOml
Cortisol
pg/1OOml
18 Hydroxy-
cortisol 88
ng/lOOml 200
BasalBasalo.1 1.0 10 Basal BasalO.1 1.0 10
ACTH, ng/kg/min
Fig. 1. Corticosteroid responses to ACTH (0.1, 1.0 and 10.0 ng/kg/min)
in Patients I (—) and 2 (---) before treatment (A) and after 4 weeks of
dexamethasone (0.5 mg 4 times daily). (B) Shaded areas in A represent
responses to ACTH in 8 normal subjects. Values are means SD.
(Reproduced from Ref. 2.)
sodium content in relation to other, more common types of
hypertension, particularly essential hypertension.
Over the years great interest has been shown in a possible
involvement of sodium chloride in the pathogenesis of essential
hypertension [3]. First, the rise in blood pressure with age
observed in most westernized societies and the high prevalence
of hypertension in these populations has been attributed to
excessive dietary intake of sodium. Linked with this idea is the
suggestion that only a proportion of individuals within a popu-
lation might be "salt sensitive" and thus might develop hyper-
tension on this basis. Moreover, a "threshold" of sodium
intake might exist above which hypertension develops. An
obviously related idea, although not a necessary corollary, is
that dietary sodium restriction might be effective in reducing
arterial pressure. Second, there might be a renal abnormality
central to the pathogenesis of hypertension, one that requires
that systemic blood pressure be elevated for the preservation of
sodium balance. Third, many abnormalities of transmembrane
electrolyte transport have been described in essential hyperten-
sion. Again, these derangements might be involved in various
ways in the pathogenesis of hypertension; these several obser-
vations and hypotheses are not necessarily mutually exclusive.
The renin-angiotensin system is also intricately related to
sodium balance [4]. Sodium losses stimulate this system; in-
creased renin secretion from the kidney results in a rise in
angiotensin II. With many other actions, the increase in angio-
tensin II helps to sustain arterial pressure and, by promoting
aldosterone secretion, restores sodium homeostasis.
More recently, the atrial peptide system has excited intense
interest and research [5]. Atrial peptides cause a natriuresis and
diuresis, lower arterial pressure, diminish the secretion of renin
and aldosterone, and oppose several of the actions of angioten-
sin II and aldosterone. For these reasons, it has been proposed
that the atrial peptide system antagonizes the renin system and
is designed to deal promptly with fluid and volume overload.
Assessment of the total-body content of sodium (and of potas-
sium) might facilitate insight into these pathogenetic mecha-
Table 1. Biochemical studies in the patients being discussed
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nisms and could provide approaches to treatment, not only of
essential hypertension but also of other hypertensive syn-
dromes [6].
Methodologic considerations
Measurements have been made both of total exchangeable
sodium and potassium (NaE and KE) and total-body sodium
and potassium (TBNa and TBK). Total exchangeable sodium
and potassium have been assessed by isotope dilution after the
administration of the respective isotopes 24Na and 43K followed
by equilibration [7]. Total-body potassium has been measured
employing a whole-body counter to detect the naturally occur-
ring isotope 40K [81. Total-body sodium has been measured
using the whole-body counter immediately after activation of
sodium in vivo by neutron bombardment [9].
Our observations have shown that, as might be expected,
TBNa consistently exceeds NaE by some 15% in the middle of
the range [10]. This excess probably represents a large pool of
nonexchangeable (or very slowly exchangeable) sodium in
bone. Our findings in humans are paralleled almost exactly by a
similar excess of TBNa over NaE in rats. We showed a close
concordance between TBNa measured by neutron bombard-
ment and by chemical analysis following ashing of carcasses
[11]. Our findings in humans show that TBK exceeds KE by
approximately 5% in the middle of the range [12]. In none of the
syndromes studied in humans, such as essential hypertension,
renal hypertension, and primary hyperaldosteronism, has evi-
dence been found of variation in the proportion of nonex-
changeable sodium or potassium. Thus qualitatively, similar
information is obtained whether total-body or exchangeable
sodium and potassium are measured.
Serial estimation of body sodium and potassium content in
the same person at different stages of the disease, as Dr. Fraser
already described for dexamethasone-suppressible hyperaldo-
steronism, permits the greatest precision of measurement. To
compare body sodium and potassium content between different
people, however, one must correct for individual variations in
body size and shape. Although there is no entirely satisfactory
frame of reference, we have found that either body surface area
or leanness index (height3 — weight) is most suitable [10]. Both
of these indices give similar values when used to express either
body sodium or potassium. In many of the studies of hyperten-
sive patients that I shall present here, total-body or exchange-
able sodium or potassium have been expressed as a percentage
of the value predicted for a normal individual of similar body
size and shape. In an extensive series of normal individuals
from Berne, Switzerland, and Glasgow, Scotland, no detectable
relationship was found between NaE and arterial pressure [10].
Mineralocorticoid-induced hypertension
The classic form of mineralocorticoid-dependent hyperten-
sion in humans is Conn's syndrome [13]. In this disease
hypersecretion of aldosterone by an adrenocortical adenoma
gives rise to high blood pressure, which is accompanied by
sodium retention and potassium depletion. Renin secretion is
suppressed, and there is a characteristic and often diagnostic
interrelationship between low values for plasma renin and
angiotensin II on the one hand and high circulating levels of
plasma aldosterone on the other [141. In this condition more
than in any other, if a connection exists between changes in
• ..$ •S
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Fig. 2. Total exchangeable sodium expressed in relation to leanness
index (%) plotted against mean arterial pressure (diastolic + 1/3 pulse
pressure) in 29 patients, all of whom were later proved to have an
aldosterone-secreting adenoma. Solid circles = measurements made
without treatment; open circles = measurements made in 20 of these
patients after at least one month's treatment with either spironolactone
or amiloride. In the untreated patients, mean exchangeable sodium is
clearly expanded, and there is a significant positive correlation with
arterial pressure. During treatment with the potassium-conserving and
natriuretic agents, arterial pressure falls in proportion to the fall in
exchangeable sodium. (Reproduced from Ref. 6.)
body sodium and arterial pressure, we should find an overall
expansion of body sodium content and a positive correlation
between body sodium and blood pressure.
Indeed, we have confirmed this relationship. In a substantial
series of untreated patients with this disease (Fig. 2), both NaE
and TBNa were clearly increased; conversely, TBK and KE
were decreased [6, 15]. In this series we also found a significant
positive correlation between the degree of expansion of body
sodium and the level of the arterial pressure. Although not
proof, these findings are consistent with a cause-and-effect
relationship. We obtained further evidence of a causal relation-
ship by treating patients who had primary aldosteronism with a
potassium-conserving and natriuretic agent such as spironolac-
tone or amiloride for at least one month before operation (Fig.
2). Body sodium content decreased concurrently with a fall in
arterial pressure [6, 15]. A similar result is achieved by surgical
excision of the tumor and consequent correction of the aldos-
terone excess, Restoration of normal levels of aldosterone also
corrects body sodium content, and arterial pressure falls in
proportion. The fall of body sodium content with therapy
occurs simultaneously with proportional decreases in total-
body water, extracellular fluid volume, and plasma volume [6,
15, 16].
Dr. Fraser already has mentioned in the two case presenta-
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tions similar relationships between shifts in body sodium con-
tent and arterial pressure in dexamethasone-suppressible aldo-
sterone excess. Other, rare syndromes of mineralocorticoid
excess similarly show expansion of body sodium content in the
untreated state as well as a decrease in arterial pressure in
parallel with a fall in body sodium with therapy. Such syn-
dromes include 17-alpha-hydroxylase deficiency and 11-beta-
hydroxylase deficiency [6]. In both of these syndromes, cortisol
synthesis is defective; consequently ACTH output is excessive
and results in overproduction of ACTH-sensitive mineralocor-
ticoids. Similar findings have been described with excessive
ingestion of an exogenous mineralocorticoid, licorice [17].
Although body sodium and potassium content are statistically
related to arterial pressure in syndromes of mineralocorticoid
excess, we should be cautious about concluding that there is a
cause-and-effect relationship between these phenomena [15].
"Idiopathic aldosteronism"
I now wish to digress briefly to consider a problem that
relates to both mineralocorticoid hypertension and essential
hypertension. About 25% of patients with high blood pressure,
elevated plasma aldosterone, and low plasma renin levels do
not harbor a typical aldosterone-secreting adenoma but have a
variety of subtle changes within the adrenal gland [6, 18—22].
Some patients have bilateral micronodular changes in the
adrenocortical zona glomerulosa, some have simple hyperplasia
of the zona glomerulosa, and some even have histologically
normal adrenal glands. This syndrome has been described
variously as "idiopathic aldosteronism," "non-tumorous aldo-
steronism," and "pseudo-primary aldosteronism." Surgical
therapy is less effective in lowering blood pressure in this
condition than it is in Conn's syndrome.
The nature of this condition has excited considerable argu-
ment over the years. In striking contrast to the findings in
Conn's syndrome and the other forms of mineralocorticoid
excess, body sodium content in this condition is either normal
or only marginally elevated [20, 23]. Similarly, our studies
disclose no consistent reduction of body potassium content. At
present it seems more likely that idiopathic aldosteronism is not
a separate entity but a variant of essential hypertension.
Low-renin hypertension
Approximately 25% of patients who apparently have essen-
tial hypertension have low levels of plasma renin, often as low
as values in patients with aldosterone-secreting adenomas [6,
24, 25]. This observation has led to speculation that an excess of
an as-yet-unidentified mineralocorticoid or corticoid might be
responsible in this group of patients both for the hypertension
and the renin suppression. In most of these patients, however,
no such mineralocorticoid excess can be demonstrated. Fur-
thermore, the mean body sodium content is not increased, nor
is body potassium content decreased [18, 23]. Consistent with
these findings for body sodium and potassium is the finding that
neither extracellular fluid nor plasma volume is expanded [26].
Similarities among essential hypertension, low-
renin hypertension, and idiopathic aldosteronism
Given the physiologic observations in several hypertensive
syndromes, we proposed that low-renin hypertension and idio-
pathic aldosteronism—and even essential hypertension—might
be closely similar one to another [22]; indeed, these three
disorders might form a continuum. By contrast, Conn's syn-
drome appears to be a distinct entity. These notions were
reinforced when we examined these various entities. In un-
treated, tumorous Conn's syndrome, the relationship between
plasma aldosterone and plasma angiotensin II was inverse [14,
27], as would be predicted if there were autonomous (or largely
autonomous) overproduction of aldosterone, which inhibits
renin secretion. In sharp contrast, the correlation between
angiotensin II and aldosterone was positive in patients with
"idiopathic" aldosterone excess [14, 27]. This observation
indicated that in the latter condition, the physiologic relation-
ship between the renin-angiotensin system was more nearly
normal, and that angiotensin II probably was still responsible,
at least in part, for regulating aldosterone secretion.
Infusion of angjotensin II, which in normal individuals stim-
ulates aldosterone secretion, has little or no effect on aldo-
sterone in true Conn's syndrome. In contrast, however, an-
giotensin II stimulates aldosterone more briskly in essential
hypertension than in subjects with a normal blood pressure.
Plasma aldosterone rises even higher in response to angiotensin
II in "idiopathic" aldosteronism than in essential hypertension.
True tumorous Conn's syndrome and "idiopathic" aldosteron-
ism thus lie at opposite ends of a spectrum with respect to the
aldosterone responses to angiotensin II [14, 18, 27, 28].
Oi-thostasis similarly increases plasma aldosterone concen-
tration in normal subjects and in patients with essential hyper-
tension, low-renin hypertension, or idiopathic aldosteronism.
In patients with Conn's syndrome, by contrast, orthostasis
usually produces little or no alteration in plasma aldosterone
[14, 271. In normal persons and in patients with essential
hypertension (whether with normal or low levels of renin) or
"idiopathic" aldosteronism, renin falls progressively with age
[14, 23, 27]. Neither we nor any other group has demonstrated
a relationship between renin and age in tumorous Conn's
syndrome.
These various features have provided a basis for several
statistical appraisals, one of which will be discussed in more
detail by Dr. Gordon Murray. Such statistical analyses have
supported the notion of a basic distinction between Conn's
syndrome and the other conditions I mentioned [14]. These
observations have led us to conclude that artificial distinctions
have been made between essential hypertension, low-renin
hypertension, and "idiopathic" aldosteronism because of an
over-rigid application of diagnostic criteria that we believe are
quite arbitrary [16, 25]. This concept has important pathophys-
iologic and practical therapeutic implications. Whereas the
correct and definitive therapy for Conn's syndrome is removal
of the tumor, surgery is not indicated in "idiopathic" aldoste-
rone excess [14, 16].
Renovascular hypertension
I now want to consider a strikingly contrasting hypertensive
disease—particularly as it concerns body sodium content—
namely, hypertension associated with unilateral renal artery
stenosis. Many patients with unilateral renal artery stenosis
(that is, with an intact contralateral kidney and renal artery)
have normal plasma electrolytes and normal or near-normal
body sodium and potassium content [29]. However, in this
594 Nephrology Forum
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Fig. 3. Inverse relationship between exchangeable sodium, expressed
in terms of body surface area, and diastolic pressure, in patients with
unilateral renal artery stenosis. The 6 patients indicated by triangles
had, on the day of exchangeable sodium measurement, plasma sodium
concentrations below 135 mEq/liter. r = 0.57; P < 0.01. (Reproduced
from Ref. 30.)
disorder, especially in patients in whom blood pressure rises
considerably, renal sodium wasting leads to progressive sodium
depletion [29, 30]. Sodium loss can be marked in patients with
acute, severe, unilateral renal artery stenosis or occlusion. In
its most pronounced form, patients can present with a "hypo-
natremic hypertensive syndrome," with considerable depletion
of body sodium and potassium, hyponatremia and hypoka-
lemia, marked elevation of peripheral plasma renin and angio-
tensin II, and secondary aldosterone excess [29, 30]. In these
circumstances, the severe renal artery lesion provides an in-
tense stimulus to renin secretion; consequently there is a
pronounced rise in plasma angiotensin II. Blood pressure
increases progressively while sodium is lost from the contralat-
eral normal kidney because of pressure natriuresis and possibly
also because of the direct renal action of very high circulating
levels of angiotensin II and vasopressin. Secondary aldosteron-
ism ensues, with consequent potassium depletion added to the
sodium depletion. Renin secretion is further stimulated by the
losses of sodium and potassium. This vicious cycle can be
broken by relieving the renal artery stenosis, removing the
diseased kidney, or reducing levels of angiotensin II with a
converting enzyme inhibitor. In a large series of patients with
hypertension associated with unilateral renal artery stenosis,
the correlation between arterial pressure and body sodium
content was an inverse one, with the most markedly hyperten-
sive patients having substantial sodium depletion [30—32] (Fig.
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Fig. 4. Total exchangeable sodium in relation to systolic pressure in
untreated patients with essential hypertension (r = 0.44; P < 0.001).
(Reproduced from Ref. 6.)
3). These findings suggest that, when systemic hypertension
arises by a mechanism that does not primarily involve sodium
retention, there is a tendency toward sodium depletion, with
pressure natriuresis as the predominant cause.
Essential hypertension
Next I wish to examine the relationship between the level of
arterial pressure and body sodium content in essential hyper-
tension. We already have seen that in normal individuals no
correlation exists between body sodium content and the level of
systolic or diastolic arterial pressure [10]. In essential hyper-
tension, irrespective of plasma renin level, the mean value for
body sodium is also normal [10]. However, in a large series of
patients with essential hypertension, although the mean value
for exchangeable sodium is close to 100% of predicted normal,
a highly significant positive correlation is found between the
level of arterial pressure and concomitant exchangeable sodium
(Fig. 4). The relationship is more readily apparent in male than
in female patients.
One could argue that this relationship between arterial pres-
sure and exchangeable sodium is an artifact, and that in some
way it is related to the well-known abnormalities of transmem-
brane electrolyte transport in essential hypertension, which
could interfere with the equilibration of administered isotope
necessary for exchangeable sodium measurement. But when we
measured total-body sodium by activation analysis (which does
not involve the administration or equilibration of isotope), we
found the same relationship as with exchangeable sodium.
Total-body sodium in essential hypertension is, on average,
close to 100% of predicted normal, and a highly significant
positive correlation exists between the level of blood pressure,
systolic or diastolic, and the value for body sodium content
[10].
Despite this overall good correlation, I should emphasize that
in young, mildly hypertensive patients, body sodium content is
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Fig. 5. Systolic and diastolic blood pressure (BP) and exchangeable
sodium (NaE, expressed as percentage of predicted normal value) in 20
normal subjects and 20 young hypertensives matched for age, gender,
and leanness. Mean SDplotted. Exchangeable sodium is significantly
lower in the hypertensives (P < 0.05). (Data from Refs. 9 and 33.
Reproduced from Ref. 33.)
distinctly low. Figure 5 illustrates the values for blood pressure
and exchangeable sodium in 20 young hypertensive patients
(under 36 years) who were matched for age, weight, gender, and
leanness with 20 normotensive individuals. Whereas the nor-
motensive subjects had a normal value for exchangeable so-
dium, the hypertensives manifested significantly depressed
levels of exchangeable sodium [10, 33].
Interpretation of these findings has been difficult. One possi-
bility is that the physiologic changes that occur at different
stages of essential hypertension mimic the alterations reflected
in the two contrasting diseases, unilateral renal artery stenosis
and Conn's syndrome. We could hypothesize that early in
essential hypertension the rise in blood pressure is initiated by
mechanisms that are independent of sodium retention and that
the high blood pressure pushes sodium out of the body in a
manner similar to that observed in renovascular hypertension.
Later in the course of the disease, possibly as a result of
hypertension-induced renal changes, the hypothesis suggests,
the high blood pressure becomes sodium dependent because of
a tendency to sodium retention.
These speculations imply that dietary sodium restriction in
the treatment of hypertension is likely to be more effective in
the more severe and chronic cases, in which sodium retention
has occurred. I have asked my colleagues, Drs. A. M. Richards
and G. D. Murray, to elaborate on these issues. Dr. Richards
will review the data on the hypotensive effect of salt restriction,
and Dr. Murray will describe our attempts to correlate the
findings in several of the entities I described.
DR. A. M. RICHARDS (New Zealand Medical Research
Council and Welicome Visiting Clinical Research Fellow, MRC
Blood Pressure Unit, Western Infirmary): Does moderate so-
dium restriction lower blood pressure? This question was
addressed by Grobbee and Hofman, who analyzed data from a
total of 584 subjects in 13 trials of moderate sodium restriction
in both normotension and hypertension [34]. The mean age of
participants in these trials varied from 16 to 60 years. Mean
reduction in daily sodium intake varied from 21 to 170 mEq.
Initial average systolic and diastolic pressures varied from 103
to 175 mm Hg and 61 to 112 mm Hg respectively. Five of the
trials examined normotensive subjects. Hence the authors were
able to analyze the effects of a broad range of "moderate"
sodium restriction in subjects of different ages who exhibited a
broad spectrum of initial blood pressures. A significant fall in
arterial pressures was achieved in only 3 of the 13 trials. The
mean changes in systolic and diastolic pressures were only —3.6
(range, —0.5 to —10.0) and —2.0 (range, +3.2 to —7.0) mm Hg
respectively. Changes in arterial pressure were not related to
reductions in daily sodium intake, but rather to initial blood
pressures and age: older and more hypertensive subjects were
more likely to respond to moderate sodium restriction with a
fall in blood pressure. The finding of greater reductions in blood
pressure in patients with higher initial blood pressures is
consistent, regardless of therapy, in essential hypertension and
might, at least in part, reflect regression to the mean. These
findings [34] agree with those in the Royal Society of Medicine
Services 1986 publication concerning dietary salt and hyperten-
sion, in which data from 8 trials of sodium restriction in patients
with essential hypertension and a further 8 in normotensive
subjects are described [35]. Although most trials have been
shorter than 2 months in duration, the results generally lead to
the conclusion that modest dietary sodium restriction, at least
for relatively brief periods, probably is not effective therapy in
itself for hypertension in young and mildly hypertensive pa-
tients. This does not detract from its value as an adjunct to
antihypertensive pharmacotherapy. A specific subgroup of
hypertensive patients with a predictable, clinically significant
hypotensive response to sodium restriction might exist, but that
group remains to be defined.
A number of studies suggest possible mechanisms that might
partly explain the overall disappointing response to sodium
restriction in hypertensive patients. Richards et al conducted a
detailed study of 12 patients with essential hypertension [36].
Ambulatory continuous intra-arterial pressure recording, to-
gether with hourly blood sampling for plasma hormones, were
employed over 24 hours. Overall, the group showed no signif-
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Fig. 6. Regression lines relating plasma renin activity and angiotensin
II (log scale) to plasma aldosterone in 12 patients (n 10 for
angiotensin II) on a control diet and a sodium-restricted diet. Each
regression line was constructed from 24 hormone samples drawn hourly
for 24 hours. Slopes of regression lines increased significantly with
sodium restriction overall (P < 0.01 for angiotensin II; paired t-test).
(Reproduced from Ref. 41.)
icant change in arterial pressures between control and sodium-
restricted phases. A close positive correlation was found,
however, between individual changes in plasma renin activity
and diastolic arterial pressure. That is, subjects with little rise in
renin activity during sodium restriction exhibited a fall in
diastolic pressure, whereas those with brisk renin responses
showed little change or even a rise in pressure. Similar pres-
sure-hormone relationships were seen with plasma angiotensin
II and aldosterone values. These data suggest that the hypoten-
sive response to sodium restriction is dictated, at least in part,
by the response of the renin-angiotensin-aldosterone system.
This concept is supported by Cappucio et a! [37]. In a study of
29 patients with essential hypertension, these authors found a
significant inverse correlation between blood pressure reduc-
tions induced by sodium restriction alone on the one hand, and
the additional fall in pressure caused by infusion of the angio-
tensin II antagonist saralasin, on the other. Similar corrobora-
tive data have appeared from other workers [38—401.
The patients we studied demonstrated a uniform rise in
plasma aldosterone concentration during modest sodium re-
striction (80 mEq/day), and a consistent increase in the slope of
individual regression lines relating renin and aldosterone (and
angiotensin II and aldosterone) over 24 hours [41] (Fig. 6).
Conversely, the relationship of renin (or angiotensin II) to
arterial pressure was not altered by this degree of sodium
restriction. The former finding is consistent with data demon-
strating increased aldosterone responses to infused angiotensin
II in sodium-depleted subjects [42, 43]. The latter finding
contrasts with the findings of decreased pressor responses to
infused angiotensin II in marked sodium restriction, however
Essential Idiopathic Conn's
hypertension aldoteronism syndrome
(median, (median, (median,
Variables range) range) range)
Na, K, HC03 1.9 (0.9—3,7) 2.4 (1.0—5.6) 4.6 (1.8—6.6)
Na, K, HCO3, All 1.8 (0.3—4.1) 2.6 (1.1—4.0) 5.0 (1.8—8.0)
Na, K, HC03,
NaE, KE 2.2 (0.6—4.5) 3.1 (1.5—5.2) 5.2 (1.9—9.4)
Na, K, HC03,
NaE, KE, All 2.4 (0.9—4.5) 3.2 (1.6—5.2) 5.4 (1.8—9.7)
[43]. Hence modest sodium restriction (to an intake of approx-
imately 80 mEq sodium/day) may, at least in the short term,
cause uniform activation of the renin-angiotensin-aldosterone
system and produce increased aldosterone responses to angio-
tensin II. Still, such sodium restriction might fail to reach the
threshold of sodium depletion at which the pressor effects of
angiotensin II are reduced. These mechanisms could partially
account for the small and inconsistent hypotensive effect of
modest sodium restriction in normal subjects and in patients
with essential hypertension.
DR. G. D. MURRAY (Senior Lecturer in Medical Statistics,
University of Glasgow): Dr. Robertson pointed out that the
range of values for exchangeable sodium and potassium was
similar in "idiopathic aldosteronism" and essential hyperten-
sion but differed in Conn's syndrome. Looking at individual
variables does not necessarily give a complete picture, how-
ever, because it ignores the correlations between those varia-
bles. The aim of our study was to examine "idiopathic aldoste-
ronism" and essential hypertension more closely to determine
whether the similarity between the two syndromes was still
apparent when we analyzed several variables simultaneously
[44].
We studied 89 patients with essential hypertension, 22 pa-
tients with "idiopathic aldosteronism," and 34 patients with
surgically proved Conn's syndrome. The statistical evaluation
used Mahalanobis' distance [45], a multivariate statistic that
can be thought of as measuring how atypical an individual's set
of measurements (NaE, KE, etc.) are relative to a reference
population (in our application, the essential hypertension
group). This distance takes into account the correlations be-
tween variables. For example, a plot of serum potassium (K)
against bicarbonate (HC03) for the 89 patients with essential
hypertension revealed a negative correlation. This meant that,
although a value of 3.5 mEq/liter for K was not abnormally low
for the group, and a value of 25 mEq/liter for HC03 was not
abnormally low for the group, the combination of these values
would be exceptional. A patient with this combination would
therefore lie a long way from the group with essential hyper-
tension in terms of Mahalanobis' distance.
We calculated the Mahalanobis distance of each patient from
the essential hypertension group for each of a number of sets of
variables. The distances for the patients with essential hyper-
tension provided a reference range, and the spread of distances
for the patients with "idiopathic aldosteronism" and Conn's
syndrome was compared to this reference. The results are
summarized in Table 2.
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Fig. 7. A Total-body sodium (mmol/kg) during the first 16 weeks of life of male SHR and WKY. SHR had significantly higher levels than WKY
at each age measured. This difference became significantly greater after about 5—6 weeks of age (see Ref. 51). B Total-body sodium (mmol/kg)
during the first 16 weeks of life in male SHR-WKY F2 rats that at 16 weeks of age are either in the hypertensive (mean 180 5 mm Hg) or
normotensive (mean 135 3 mm Hg) ranges. No tendency to sodium retention was observed at any time during the development of hypertension,
and there was no difference overall between the two groups. (Reproduced from Ref. 51.)
For each set of variables considered, the range of values of
Mahalanobis' distance for the group with "idiopathic aldoste-
ronism" is close to that for the group with essential hyperten-
sion, whereas many of the values for patients in the group with
Conn's adenoma lie well outside the range of values observed in
the group with essential hypertension. This further emphasizes
the similarity of "idiopathic aldosteronism" with essential
hypertension, and the distinction between these conditions and
Conn's syndrome.
DR. ROBERTSON: The patients presented by Dr. Fraser are
examples of a genetically determined abnormality of aldoste-
rone secretion that results in an increase in total-body sodium
and in hypertension. This sodium-dependent form of genetic
hypertension appears to be inherited in an autosomal dominant
fashion and controlled by a limited number of genes [46]. In
contrast, essential hypertension is a disorder in which multiple
genetic factors exert a relatively minor direct effect on blood
pressure, which is strongly influenced by environmental factors
[47]. The relative importance of genetic and environmental
factors as causes of abnormal total-body sodium content and
abnormal sensitivity of blood pressure to salt intake are un-
known. These problems would best be investigated by sequen-
tial studies of total-body sodium and blood pressure under
strictly controlled environmental circumstances in individual
hypertensive patients. The protracted and complex nature of
such studies makes them impractical in humans. I have asked
Dr. S. B. Harrap to describe the experimental studies in
hypertensive rats.
DR. S. B. HARRAP (Commonwealth Visiting Clinical Re-
search Fellow, MRC Blood Pressure Unit, Western Infirmary):
The availability of the Japanese spontaneously hypertensive rat
(SHR), in which genetic factors exert a strong influence on
blood pressure [48], provides the opportunity for an examina-
tion of the relationship between total-body sodium and blood
pressure under standardized environmental conditions. In this
way, genetically determined abnormalities of sodium balance
can be detected. Early studies noted that a high sodium intake
from a young age exacerbated the hypertension in SHR, and the
total-body sodium of mature SHR with established hyperten-
sion was significantly greater than that in control normotensive
rats [49, 501. Recent sequential and noninvasive studies of
total-body sodium in SHR from 1 to 16 weeks of age have
helped define changes in total-body sodium during the develop-
ment of hypertension [51, 52]. At all ages, the total-body
sodium (expressed as mEq/kg body weight) is greater in SHR
than in control normotensive Wistar-Kyoto (WKY) rats (Fig.
7A). Of particular interest is the exaggeration of this difference
in total-body sodium between SHR and WKY at 4 to 6 weeks of
age, that is, during the early developmental phase of hyperten-
sion. This apparent relative sodium retention is not explained
by greater weight gain in WKY and also has been noted in
metabolic studies of sodium balance in SHR at this age [53].
These findings suggest that sodium retention might be an
important pathogenetic abnormality in SHR hypertension.
No true control strain exists for the SHR, and it is possible
that phenotypic differences of total-body sodium between SHR
and WKY might be independent of the genetic differences
responsible for hypertension. To investigate this problem,
detailed cross-breeding studies have been performed in which
the genes of SHR and WKY were mixed to produce an F2
generation. The blood pressure of mature F2 rats ranges from
normotensive to hypertensive levels. If the abnormalities of
total-body sodium in SHR play a primarly role in the genetic
hypertensive process, one would expect that mature hyperten-
sive F2 rats would have higher total-body sodium levels than do
mature, normotensive F2 rats. In fact this is not the case. More
important, sequential measurements of total-body sodium in
these two groups failed to reveal any tendency toward sodium
retention in the F2 rats that eventually became hypertensive,
that is, those carrying the hypertensive genes inherited from the
SHR (Fig. 7B).
Some basic conclusions can be drawn from these studies.
First, the high total-body sodium and sodium retention in the
SHR do not appear to be responsible for the hypertension in
this strain. This does not, however, exclude an internal redis-
tribution of sodium as important in the hypertensive mechanism
of SHR. In addition, these genetic experiments do not negate an
environmental effect of sodium on SHR blood pressure. It is
60 60
45
SHR
- WKY
Salt, volume, and hypertension 597
Hypertensive F2
Normotensive F2
45
1 8 16
598 Nephrology Forum
worth noting, however, that mild to moderate sodium restric-
tion does not affect the level of hypertension of SHR [54]. In
regard to salt restriction, the SHR contrasts with the Dahl
salt-sensitive rat strain, which exhibits a genetic predisposition
to changes in blood pressure as a result of alterations in sodium
intake [55]. Second, even under strictly defined environmental
circumstances, phenotypic differences between hypertensive
and normotensive individuals might be quite unrelated to the
difference in blood pressure, even if such a link seems obvious
and logical. Finally, when considering a multifactorial disease
such as essential hypertension, we must consider carefully the
complex nature of genetic and environmental interactions as
well as the secondary effects of raised blood pressure per se.
DR. ROBERTSON: Dr. Lever will conclude the formal remarks
by presenting our views on the alternative hypothesis that
explains the relationships among sodium, volume, and hyper-
tension.
DR. A. F. LEVER (Unit Director, Consultant Physician, MRC
Blood Pressure Unit, Western Infirmary): No salt hypothesis,
including one of our own [31, wholly or satisfactorily explains
the pathogenesis of essential hypertension. As we have just
heard, mineralocorticoids cause hypertension in humans and
animals, and it may be that they do so by their sodium-retaining
effect. In support of the relationship between volume and
hypertension are these observations: (1) the degree of sodium
retention relates to the rise of arterial pressure in essential
hypertension and Conn's syndrome [15, 56]; (2) a low-sodium
diet in animals injected with mineralocorticoid prevents a rise of
blood pressure [57]; and (3) in patients with Conn's syndrome,
diuretics reduce arterial pressure, and the fall of pressure is
related to the fall of NaE [15]. However, arguing against a
simple role for increased body sodium is the absence of sodium
retention in a small number of patients with Conn's syndrome
[15] and the lack of a relationship in time between sodium
retention and the rise of blood pressure in this syndrome.
Sodium retention may be present long before pressure rises,
and pressure actually can be rising when sodium balance is
negative [58].
Is mineralocorticoid hypertension a model for essential hy-
pertension in humans? Some electrolyte abnormalities are
present in both conditions; others are not. As in Conn's
syndrome, NaE relates positively to arterial pressure in essen-
tial hypertension, whereas body potassium and plasma potas-
sium relate negatively [56, 59]; also blood pressure can be
lowered in essential hypertension by dietary sodium depriva-
tion or by diuretics. Although these observations hint at mm-
eralocorticoid excess or at an abnormality in the metabolism or
dietary content of sodium, no known mineralocorticoid is
present in excess in essential hypertension (except possibly
aldosterone during states of abnormally increased dietary so-
dium). More important, on average sodium is not retained
abnormally in essential hypertension [59]. Indeed, as Dr. Rob-
ertson pointed out, a small insignificant expansion found in
older patients is balanced by a small significant reduction of
NaE in young male patients [56, 59]. In women no relationship
between NaE and arterial pressure is apparent, although plasma
potassium is inversely related to pressure [56]. These observa-
tions are an inadequate basis for a claim that sodium retention
is a necessary step in the development of essential hyperten-
sion. Guyton and colleagues have suggested that equilibrium
1. Primary cause p Na retention p Hypertension
2. Hypertension Abnormal relation of NaE and blood pressure
3. Primary cause Abnormal cell electrolytes Abnormal NaE
Hypertension
4. Primary cause Abnormal relation of NaE & BP and/or
abnormal cell electrolytes
" Hypertension
Fig. 8. Fourpossible routes to hypertension.
could be reached with hypertension and 100% normal NaE
because the gain in the pressure-natriuresis mechanism is 100%
[601. In other words, after a period of sodium retention, blood
pressure rises and NaE returns exactly to its original value.
This does not explain the low level of body sodium in young
males with hypertension or the absence of a relationship
between NaE and arterial pressure in women [56, 59].
Four hypotheses relating sodium and hypertension are sum-
marized in Fig. 8. In the first, sodium retention is a necessary
step in the sequence of events producing hypertension. Evi-
dence suggests that this hypothesis is unlikely. The second
hypothesis is the reverse of the first: hypertension causes an
abnormal relationship between NaE and arterial pressure. The
clear relationship between NaB and pressure in older patients,
and the absence of such a relationship in younger patients,
lends some support for the idea. The finding of abnormal
electrolyte transport in the blood cells of normotensive off-
spring of hypertensive parents makes it unlikely, however, that
all electrolyte abnormalities in essential hypertension are a
consequence of raised blood pressure.
The third hypothesis is based on indirect evidence from
many, and sometimes contradictory, reports. One series of
experiments hints that a primary abnormality of electrolyte
transport or of the cell membrane (leading to a secondary
abnormality of electrolyte transport) in blood cells is general-
ized and that by affecting vascular smooth muscle, this mem-
brane disorder causes vasoconstriction [61—65]. Some have
claimed that a circulating agent might affect electrolyte trans-
port and thus ultimately cause essential hypertension [66, 67]. A
mechanism of this sort might explain the abnormal relationship
between sodium and arterial pressure, and could be either a
necessary step (hypothesis 3) or, as the fourth hypothesis
suggests, an epiphenomenon in the sequence of events causing
hypertension. Militating against the first of these suggestions is
evidence that the change of cell sodium is insufficient to cause
the vasoconstriction [68].
Insulin has been suggested as a pathogenetic agent in essen-
tial hypertension [65, 69, 70]. In fact, plasma insulin levels are
increased in patients with essential hypertension and in obese
patients with raised arterial pressure [70, 71]. Insulin could act
directly on sodium balance or it could cause abnormal sodium
transport [70]. Another possibility is that it acts not by its
electrolyte effect but as a growth factor for vascular smooth
muscle [72]. I have argued elsewhere that insulin produces
hypertrophy of resistance vessels and thereby raises blood
pressure slowly and progressively [65] through the positive-
feedback mechanism proposed in the 1950s by Folkow [73].
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Excess growth hormone, which is commonly associated with
hypertension in humans [74], could act in a similar fashion [65].
In summary, clear evidence exists for an abnormal relation-
ship between arterial pressure and electrolytes in patients with
essential hypertension. This disturbance is apparent for the
body content of sodium and potassium, for plasma concentra-
tions of sodium and potassium, and for the transport of sodium
and other electrolytes in blood cells. Also, the blood pressure of
patients with essential hypertension falls more on average than
does the pressure of normal subjects during dietary sodium
deprivation; patients with hypertension also usually respond
well to the sodium depletion produced by diuretics. There is no
widely accepted explanation linking these observations. The
evidence is insufficient to abandon any of the four hypotheses
currently being considered.
Questions and answers
DR. JEROME P. KASSIRER (Associate Physician-in-Chief, De-
partment of Medicine, New England Medical Center Hospi-
tals): It appears that we are relinquishing the notion that the
total quantity of sodium in the body is causally related to
hypertension, and that we are adopting a concept positing that
alterations in volume may be an epiphenomenon and that some
other kind of mechanism is more important in the genesis of
hypertension, particularly in essential hypertension. Do you
think the recent observations on calcium in hypertension could
represent a similar kind of epiphenomenon?
DR. ROBERTSON: Let me deal with the first part of your
question: I still accept the idea that in the later states of
essential hypertension there may be a tendency toward sodium
retention and volume expansion, that this expansion might
contribute to the high blood pressure and that, in these circum-
stances, sodium restriction might be important in lowering
arterial pressure. I think, however, that our data diminish the
role for sodium retention, or a tendency thereto, as being
important early in the pathogenesis. Data presented at the
meeting of the International Society of Hypertension in
Heidelberg in 1986 [75] have left me with considerable uncer-
tainties concerning calcium in essential hypertension. Morris
and McCarron found that giving calcium carbonate, 1 g daily for
12 weeks, produced an average fall of only 4 mm Hg in standing
systolic pressure and yielded no significant changes in standing
diastolic or in lying systolic or diastolic pressure. Neither
Nowson and Morgan of Melbourne nor Zoccali of Italy [75]
found an effect on blood pressure by administering calcium salts
to patients with essential hypertension, McCarron's data on
calcium in this condition certainly could represent an epiphe-
nomenon. I prefer to regard our data on sodium reduction in
mild essential hypertension as a physiologic consequence of the
high blood pressure at that stage of the disease. I doubt that this
comes strictly under the definition of an epiphenomenon.
DR. KASSIRER: Because compensatory responses might be
involved, sodium restriction might not have much of an effect
on blood pressure in hypertensive patients. Does that imply that
in the diuretic-treated patients, in whom there is a drop in blood
pressure, the compensatory mechanisms are not sufficient to
counter the effect of the sodium depletion?
DR. RICHARDS: Rather than stating that sodium restriction is
ineffective in treating essential hypertension, it is more correct
to say that there is a spectrum of response. A clinical trial of
sodium restriction in a given patient with essential hypertension
is probably still worthwhile, but you probably should not have
great expectations for its success as a monotherapy, particu-
larly in young people. With respect to your question about
diuretics, I don't think that anybody has compared the kind of
sodium loss that is induced by modest dietary sodium restric-
tion to that induced by the standard diuretic regimen.
DR. LEVER: There is another difference: diuretics are usually
tested in more severely hypertensive patients than is dietary
sodium deprivation. Because blood pressure falls more in
hypertensives whose initial blood pressure is higher, the com-
parison of diuretics with salt depletion is not a comparison of
like with like. As Dr. Richards says, it would be useful to
produce a comparable reduction of body sodium by the two
methods in the same group of patients in a crossover study and
then compare the effect on blood pressure.
DR. ROBERTSON: In collaboration with Dr. Manhem, we
studied exchangeable sodium in the spontaneously hyperten-
sive rat and the effect of chlorothiazide [76]. Although chloro-
thiazide significantly reduced blood pressure, that decrease was
not paralleled by a comparable lowering of exchangeable so-
dium,
DR. LEVER: Can lessons be learned from the specificity of a
therapeutic agent? Patients with pernicious anemia respond
well to B12, but not at all to iron. We infer, correctly, that
deficiency of B12, not iron, is responsible for the disease.
Essential hypertension is different: patients respond well to a
large number of different specific agents—to calcium channel
blockers, beta-blockers, alpha2-antagonists, alpha1 -antagonists,
converting enzyme inhibitors, and diuretics—as well as to a
reduction in dietary salt. Because of this variety of therapeutic
possibilities, success with dietary salt deprivation no more
reveals a primary mechanism (excess dietary salt) than does
success with a beta-blocker (overactive beta-agonist mecha-
nism), or success with an ACE inhibitor (overactive renin-
angiotensin mechanism). Essential hypertension cannot have 6
primary causes (although there could be 6 links in the chain of
events causing the disease). The success of therapists in design-
ing 6 highly effective agents has limited interpretation based on
the success of any one agent.
DR. FRASER: Are we certain that the response of blood
pressure during sodium chloride restriction is due to the sodium
ion alone? Passmore et al, using the DOCA-salt-treated rat
model of hypertension, found higher blood pressures in animals
given sodium chloride than in those receiving sodium associ-
ated with other anions (phosphate, bicarbonate, aspartate, and
glycinate) [77]. These authors postulate an important role for
the chloride ion. Has anybody looked at the role of the chloride
ion in humans?
DR. ROBERTSON: The literature contains occasional case
reports of patients with peptic ulcer who, when they ingest large
quantities of sodium bicarbonate, develop hypertension with
suppression of plasma renin [78]. I know of no direct evidence.
DR. HARRAP: One of the interesting features of essential
hypertension is the apparent reduction in total-body sodium in
younger patients. Is there any evidence that during the devel-
opment of "idiopathic aldosteronism," as we now define it,
there is a reduction in total-body sodium? If so, might this
decrease cause adrenal hyperplasia? Such a finding would go a
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long way toward linking these two conditions as part of a
continuum.
DR. LEVER: Is it not more likely that young patients with
essential hypertension who have subnormal body sodium, older
patients with low-renin hypertension, and patients with "idio-
pathic hyperaldosteronism" are part of a continuum? For
reasons we do not understand, does body sodium rise more
than normally with age [10, 23] and aldosterone decrease less
[79]? As a result, we find in older patients more often different
combinations of increased body sodium, decreased renin, and
higher-than-normal aldosterone. Low-renin hypertension and
so-called "idiopathic aldosteronism" may be two such combi-
nations.
DR. ROBERTSON: The data I showed were from an early
study. In a later, more detailed study, we confirmed the
previous suggestion that there was indeed a significant, albeit
slight, expansion of exchangeable sodium in "idiopathic aldo-
steronism" as compared with essential hypertension, although
it still remained substantially below the average value for
Conn's syndrome. This finding agreed with Dr. Lever's obser-
vation that "idiopathic aldosteronism," if it belongs to the
essential hypertension distribution, is probably a more severe,
later stage in which the patient has a tendency toward sodium
expansion.
DR. FRASER: Although there are close similarities between
the blood pressure-electrolyte relationship and the response of
aldosterone to angiotensin II infusion, studies in our Unit show
differences in the levels of some steroids, such as 18-hydroxy-
1 1-deoxycorticosterone, between the two conditions (Lasari-
dis, Lever, Fraser, unpublished data).
DR. KASSIRER: Do patients with non-renin-dependent hyper-
tension respond to dexamethasone?
DR. LEVER: We have tested all our patients suspected of
having primary hyperaldosteronism with dexamethasone, but
we have not tested so far those with essential hypertension.
DR. RICHARDS: Dr. Lever, if there is a factor causing
increased blood pressure, a factor associated with a rise in
exchangeable sodium (hypothesis 4, Fig. 8), why should mean
body sodium in patients with essential hypertension be only
100% of normal? Why isn't it more than 100%?
DR. LEVER: Perhaps if sodium retention is an epiphenomenon
not directly responsible for the blood pressure increase, the
simultaneous rise in blood pressure might still tend to restore
sodium balance to normal by pressure natriuresis.
Da. FRASER: The physiologic effects of varied sodium intake
in early life have been studied in the rat [80]. Salt deprivation
led to changes in sodium homeostasis and aldosterone control
and possibly also affected blood pressure. Is this evidence of an
influence of dietary sodium?
DR. LEVER: For 4 weeks Aviv and coworkers deprived very
young normal rats of sodium and then instituted a normal-
sodium diet [80]. Predictably, the aldosterone excretion rate
increased during the low-sodium period. However, when nor-
mal sodium status was restored, aldosterone excretion re-
mained well above the control group. These authors concluded
that a relatively irreversible state of hyperaldosteronism could
be produced by neonatal salt deprivation. They speculated that
this hyperaldosteronism might lead to an elevation of blood
pressure. However, no measurements of blood pressure were
reported in their paper. We repeated the experiment; to our
surprise, systolic pressure rose during the period of sodium
deprivation and fell when normal sodium intake was restored.
Aldosterone and corticosterone, however, did revert to normal
when dietary sodium intake was increased. Why did blood
pressure rise in normal young rats eating a low-sodium diet [81,
82]? An explanation suggested by Seymour and colleagues is
that dietary sodium deprivation activates the renin mechanism
to the point at which its pressor effect more than compensates
for the depressor effect of volume depletion [81]. The response
of their animals to inhibitors of the renin-angiotensin mecha-
nism lent support for the idea.
Reprint requests to Dr. R. Fraser, MRC Blood Pressure Unit,
Western Infirmary, Glasgow, Gil 6NT, Scotland, U.K.
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